This aspect is clinically relevant because many EZH2 inhibitors tested in clinical trials, such as the SAM-competitive EZH2 inhibitor tazemetostat (approved for advanced epithelioid sarcoma), primarily target the methyltransferase domain and may not fully abrogate these non-canonical oncogenic functions [32]. This evidence concerns the gene EZH2 and epithelioid sarcoma.